Meeting
2017 ASCO Annual Meeting
Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.
Authors
Ani Sarkis Balmanoukian
The Angeles Clinic and Research Institute, Los Angeles, CA
Ani Sarkis Balmanoukian , Scott Joseph Antonia , Wen-Jen Hwu , Omid Hamid , Martin Gutierrez , Rahima Jamal , Guy Heinrich Maria Jerusalem , Myung-Ju Ahn , Dong-Wan Kim , David Cunningham , Sang-We Kim , Julie R. Brahmer , Jose Lutzky , Jared Weiss , Xiaoping Jin , Joyce Antal , Ashok Kumar Gupta , Neil Howard Segal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01693562
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9085)
DOI
10.1200/JCO.2017.35.15_suppl.9085
Abstract #
9085
Poster Bd #
411
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.
First Author: Matthew D. Hellmann
Poster
2014 ASCO Annual Meeting
Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).
First Author: Edward B. Garon
Poster
2018 ASCO Annual Meeting
Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).
First Author: Jonathan Wade Goldman
Poster
2024 ASCO Annual Meeting
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.
First Author: Chunjiao Wu